Penumbra (NYSE: PEN) and Apollo Endosurgery (NASDAQ:APEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Risk and Volatility
Penumbra has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Valuation and Earnings
This table compares Penumbra and Apollo Endosurgery’s gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Penumbra has higher revenue and earnings than Apollo Endosurgery.
Institutional and Insider Ownership
70.9% of Penumbra shares are owned by institutional investors. Comparatively, 8.9% of Apollo Endosurgery shares are owned by institutional investors. 13.5% of Penumbra shares are owned by insiders. Comparatively, 74.2% of Apollo Endosurgery shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Penumbra and Apollo Endosurgery’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current ratings and price targets for Penumbra and Apollo Endosurgery, as provided by MarketBeat.
||Strong Buy Ratings
Penumbra presently has a consensus target price of $98.00, indicating a potential upside of 0.93%. Apollo Endosurgery has a consensus target price of $11.00, indicating a potential upside of 157.09%. Given Apollo Endosurgery’s higher possible upside, analysts plainly believe Apollo Endosurgery is more favorable than Penumbra.
Penumbra beats Apollo Endosurgery on 7 of the 11 factors compared between the two stocks.
Penumbra Company Profile
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.